002566.SZ
益盛药业
SZSE · Healthcare · C 制造业 · CN
CNY 6.74
−0.74%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
37.6x
Market Cap
CNY 2.23B
MomentumView details →
1D Return
−0.74%
YTD Return
−8.13%
RSI (14)
54.8
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
37.6x
Market Cap
CNY 2.23B
RSI (14)
54.8
MomentumView details →
1D Return
−0.74%
YTD Return
−8.13%
Similar companies
Latest newsMore news →
Yisheng Pharmaceutical announced its first-half 2026 results with revenue of 338 million yuan, up 3.25% year-on-year, and net profit attributable to shareholders of 26.83 million yuan, up 42.99%.11d agoYisheng Pharmaceutical initiated a product recall and launched a comprehensive self-inspection and rectification campaign across its production system.60d agoYisheng Pharmaceutical received a notice from Jilin Provincial Drug Administration on July 1, 2026, ordering the suspension of production and sales of Shengmai Injection and Bujin Tablets due to serious defects and safety hazards found during an inspection from June 26 to 28, 2026.62d ago